<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hall, Roger</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Outcomes from the CARDia Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">29-29</style></pages><abstract><style  face="normal" font="default" size="100%">No clear evidence supports routine percutaneous coronary intervention (PCI) for patients with diabetes and multivessel disease, according to 5-year follow-up data from the Coronary Artery Revascularisation in Diabetes [CARDia; ISRCTN19872154] trial. Coronary artery bypass graft surgery is favored, unless clinical features indicate that PCI is clearly preferable.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>